Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Corvus Pharmaceuticals (CRVS) Research & Development (2016 - 2026)

Corvus Pharmaceuticals' Research & Development history spans 12 years, with the latest figure at $11.2 million for Q1 2026.

  • Quarterly Research & Development rose 49.94% to $11.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.4 million through Mar 2026, up 64.48% year-over-year, with the annual reading at $33.7 million for FY2025, 73.94% up from the prior year.
  • Research & Development came in at $11.2 million for Q1 2026, up from $9.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $11.2 million in Q1 2026 to a low of $4.0 million in Q3 2023.
  • The 5-year median for Research & Development is $5.1 million (2022), against an average of $6.2 million.
  • Year-over-year, Research & Development tumbled 61.75% in 2023 and then skyrocketed 91.37% in 2025.
  • Corvus Pharmaceuticals' Research & Development stood at $4.1 million in 2022, then fell by 1.99% to $4.0 million in 2023, then soared by 49.39% to $6.0 million in 2024, then surged by 66.37% to $9.9 million in 2025, then rose by 12.44% to $11.2 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Research & Development are $11.2 million (Q1 2026), $9.9 million (Q4 2025), and $8.5 million (Q3 2025).